Related Experiment Video
Updated: Jul 8, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
1Department of Sarcoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, United States.
Abstract:
Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare tumors that arise from lipocytes in soft tissue. There is a high unmet need in patients with these liposarcomas given poor outcomes, particularly for DDLPS. WDLPS and DDLPS share important genetic and histological characteristics - most notably, the amplification of the 2 genes MDM2 and CDK4. Both genes are considered oncogenes because of their ability to shut down tumor suppressor pathways. There are multiple therapeutic approaches that aim to target MDM2 and CDK4 activity for the purpose of restoring intrinsic tumor suppressor cellular response and terminating oncogenesis. However, current understanding of the molecular mechanisms involved in WDLPS and DDLPS pathology is limited. In recent years, significant efforts have been made to refine and implement targeted therapy for this patient population. The use of patient-derived cell and tumor xenograft models has been an important tool for recapitulating WDLPS and DDLPS biology. These models also offer valuable insights for drug development and drug combination studies. Here we offer a review of the current understanding of WDLPS and DDLPS biology and its therapeutic implications.
Insights
Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare soft tissue tumors. Targeting amplified MDM2 and CDK4 oncogenes shows promise for improving outcomes in WDLPS and DDLPS patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare soft tissue tumors with poor prognoses, especially DDLPS.
- These liposarcomas share key genetic features, including MDM2 and CDK4 gene amplification, which drive oncogenesis by inhibiting tumor suppressor pathways.
Purpose of the Study:
- To review current understanding of WDLPS and DDLPS biology.
- To discuss therapeutic implications, focusing on targeting MDM2 and CDK4.
- To highlight the role of patient-derived models in advancing treatment strategies.
Main Methods:
- Review of existing literature on WDLPS and DDLPS.
- Analysis of genetic and histological characteristics.
- Examination of therapeutic strategies targeting MDM2 and CDK4.
- Evaluation of patient-derived cell and tumor xenograft models.
Main Results:
- MDM2 and CDK4 amplification are critical oncogenic drivers in WDLPS and DDLPS.
- Targeting these amplified genes offers a therapeutic strategy to restore tumor suppressor functions.
- Patient-derived models are crucial for understanding disease biology and facilitating drug development.
Conclusions:
- Despite limited understanding of molecular mechanisms, targeted therapies against MDM2 and CDK4 are being developed for WDLPS and DDLPS.
- Further research and utilization of preclinical models are essential for refining treatment approaches and improving patient outcomes in liposarcoma.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...